Literature DB >> 24919610

Indocyanine green clearance test combined with MELD score in predicting the short-term prognosis of patients with acute liver failure.

Hong-Ling Feng1, Qian Li, Lin Wang, Gui-Yu Yuan, Wu-Kui Cao.   

Abstract

BACKGROUND: Acute liver failure (ALF) is an acute severe deterioration of liver function with high mortality. Early and accurate prognostic assessment of patients with ALF is critically important. Although the model for end-stage liver disease (MELD) scores and King's College Hospital (KCH) criteria are well-accepted as predictive tools, their accuracy is unsatisfactory. The indocyanine green (ICG) clearance test (ICGR15, ICG retention rate at the 15 minutes) is a sensitive indicator of liver function. In this study, we investigated the efficacy of the ICGR15 for the short-term prognosis in patients with ALF. We compared the predictive value of ICGR15 with the MELD scores and KCH criteria.
METHODS: Sixty-nine patients who had been diagnosed with ALF were recruited retrospectively. ICGR15 had been performed by ICG pulse spectrophotometry and relevant clinical and laboratory indices were analyzed within 24 hours of diagnosis. In addition, the MELD scores and KCH criteria were calculated.
RESULTS: The three-month mortality of all patients was 47.83%. Age, serum total bilirubin and creatinine concentrations, international normalized ratio for prothrombin time, ICGR15, MELD scores and KCH criteria differed significantly between surviving and deceased patients. A positive correlation was observed between ICGR15 and MELD scores (r=0.328, P=0.006). The ICGR15-MELD model, Logit(P)=0.096XICGR15+0.174XMELD score-9.346, was constructed by logistic regression analysis. The area under the receiver operating characteristic curve was 0.855. When set the cut-off point to -0.4684, the sensitivity was 87.90% and specificity, 72.20%. The area under the receiver operating characteristic curve of the ICGR15-MELD model (0.855) was significantly higher than that of the ICGR15 (0.793), MELD scores (0.776) and KCH criteria (0.659). Based on this cut-off value, the patients were divided into two groups. The mortality was 74.36% in the first group (ICGR15-MELD≥-0.4686) and 13.33% in the second group (ICGR15-MELD<-0.4686), with a significant difference between the two groups (X(2)=25.307, P=0.000).
CONCLUSION: The ICGR15-MELD model is superior to the ICGR15, MELD scores, and KCH criteria in predicting the short-term prognosis of patients with ALF.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24919610     DOI: 10.1016/s1499-3872(14)60040-0

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  4 in total

1.  The combination of indocyanine green clearance test and model for end-stage liver disease score predicts early graft outcome after liver transplantation.

Authors:  Tang Yunhua; Ju Weiqiang; Chen Maogen; Yang Sai; Zhang Zhiheng; Wang Dongping; Guo Zhiyong; He Xiaoshun
Journal:  J Clin Monit Comput       Date:  2017-08-22       Impact factor: 2.502

2.  Human Ex-Vivo Liver Model for Acetaminophen-induced Liver Damage.

Authors:  Thomas Schreiter; Jan-Peter Sowa; Martin Schlattjan; Jürgen Treckmann; Andreas Paul; Karl-Heinz Strucksberg; Hideo A Baba; Margarete Odenthal; Robert K Gieseler; Guido Gerken; Gavin E Arteel; Ali Canbay
Journal:  Sci Rep       Date:  2016-08-23       Impact factor: 4.379

3.  Predictive Value of Indocyanine Green Plasma Disappearance Rate on Liver Function and Complications After Liver Transplantation.

Authors:  Yan Sun; Lixin Yu; Yihe Liu
Journal:  Med Sci Monit       Date:  2018-06-01

4.  Comparison of the ability of the PDD-ICG clearance test, CTP, MELD, and MELD-Na to predict short-term and medium-term mortality in patients with decompensated hepatitis B cirrhosis.

Authors:  Xiang-Pu Cheng; Jing Zhao; Yu Chen; Fan-Kun Meng; Bin Xu; Hong-Wei Yu; Qing-Hua Meng; Yan-Min Liu; Shi-Bin Zhang; Sha Meng; Jing-Yun Zhang; Jin-Yan Zhang; Zhong-Ping Duan; Su-Jun Zheng
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-04       Impact factor: 2.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.